
Saturday, March 02, 2024 1:56:27 PM
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Recent LTRN News
- Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer • Business Wire • 01/27/2025 12:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 09:05:29 PM
- Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients • Business Wire • 12/09/2024 01:15:00 PM
- Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) • Business Wire • 12/03/2024 01:00:00 PM
- Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality • Business Wire • 11/26/2024 01:45:00 PM
- Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients • Business Wire • 11/19/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:07:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 09:05:35 PM
- Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates • Business Wire • 11/07/2024 09:05:00 PM
- Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board • Business Wire • 11/05/2024 01:00:00 PM
- Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET • Business Wire • 10/31/2024 12:00:00 PM
- Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 • Business Wire • 10/23/2024 12:45:00 PM
- Lantern Pharma to Host & Participate in Two Public Webinars During October • Business Wire • 10/21/2024 12:00:00 PM
- Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA • Business Wire • 10/15/2024 01:07:00 PM
- Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers • Business Wire • 09/23/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:07:53 PM
- Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates • Business Wire • 08/08/2024 08:01:00 PM
- Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 • Business Wire • 08/07/2024 01:31:00 PM
- Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort • Business Wire • 08/05/2024 12:00:00 PM
- Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET • Business Wire • 08/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:12 PM
- Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 • Business Wire • 07/10/2024 12:30:00 PM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM
VAYK Project $700K 2024 Revenue with $150K Net Profit • VAYK • Feb 5, 2025 12:43 PM
UAV Corp (UMAV) Kicks Off Landmark "SKY" Hangar Project with Land Clearing at Costin Airport Setting Stage for Q1 2025 Groundbreaking • UMAV • Feb 5, 2025 8:30 AM
HealthLynked Corp. Releases Annual Shareholder Letter Highlighting Recent Product Development and Strategic Vision for the Future • HLYK • Feb 4, 2025 8:00 AM
Wytec Wins Multi-State Government Contract for AI Gunshot Detection • WYTC • Feb 3, 2025 7:16 AM
UAV Corp. Retains Legal Counsel to Address Legacy Debt from HTTI Era; 500 Million Authorized Shares Confirmed - UAV Corp. Delivers on Strategic Commitments • UMAV • Jan 31, 2025 1:30 PM